3-bromofluoren-9-one | CAS:2041-19-2

We serve 3-bromofluoren-9-one CAS:2041-19-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
3-bromofluoren-9-one

Chemical Name:3-bromofluoren-9-one
CAS.NO:2041-19-2
Synonyms:3-Bromofluoren-9-on
3-bromofluorenone
Fluoren-9-one,3-bromo
Molecular Formula:C13H7BrO
Molecular Weight:259.09800
 
Specification:
Appearance:Off-white to slight yellow powder
Assay:≥99.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:OLED intermediates



Contact us for information like 3-bromofluoren-9-one chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Fluoren-9-one,3-bromo physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Fluoren-9-one,3-bromo Use and application,3-bromofluoren-9-one technical grade,usp/ep/jp grade.


Related News: The World Health Organisation (WHO) describes coronaviruses as a large family of viruses ranging from the common cold to more severe diseases such as Severe Acute Respiratory Syndrome (SARS), which killed nearly 800 people globally during a 2002/03 outbreak that also started in China.Diisopropyl malonate manufacturer The fine and functional chemicals sector provides new growth drivers.2-Chloro-N-(4-chlorophenethyl)propan-1-amine hydrochloride supplier Our previous work with Retrogenix validated their technology as a uniquely powerful approach for antibody target deconvolution, and we look forward to working with Retrogenix to enhance our growing pipeline of antibody candidates.”3,5-Dibromo-4-hydroxybenzaldehyde vendor In order to find answers to these questions, our staff in the development department set about conducting a series of experiments.It is estimated that the size of China’s CMO market has reached about USD 5 billion. With the implementation and further implementation of the MAH system (the core is to separate drug marketing authorization from drug production authorization) in China, it is expected to promote the outbreak of the domestic drug CMO industry. It will grow at a rate of 20% to 30%, of which patented APIs occupy a larger proportion.